Skip to main content
  • Contact
  • Global site
  • English
  • Français
Home
  • About us
    • Corporate profile
      • Our company
      • Vision
      • Values
      • BI Innovates
      • History
      • Sustainability
      • Corporate citizenship
      • Global activities
      • Suppliers and business partners
    • Media
      • News releases
      • Image mediapool
      • Social media
      • Media contacts
      • Annual Report
      • Annual Press Conference
  • Innovation
    • Areas of expertise
      • Biological sciences
      • Structural research
      • Drug discovery support
    • Clinical research
    • Research and development sites
  • Human Pharmaceuticals
    • Cardiovascular
      • Atrial fibrillation
      • High blood pressure
      • Venous blood clots
    • Oncology
      • Lung cancer
    • Respiratory
      • Asthma
      • COPD
      • IPF
    • Metabolic diseases
      • Diabetes
    • Other
      • Continuing Health Education
      • Healthcare Providers
      • Our products
  • CHC
  • Animal Health
    • Avian
    • Bovine
    • Equine
    • Pet
      • Feline
      • Canine
    • Swine
    • Other
      • News Releases
      • Our products
  • Careers
    • Our Culture
      • Our Vision
      • AAI
      • Our Values
    • Our Development
    • Our people
      • Diversity
    • Our workplace
      • Burlington - Head Office
      • Field-based
      • Work-life balance
    • Our rewards
      • Pay
      • Benefits
      • Rewards and recognition
    • Our jobs

Search form

  •   Type 2 diabetes
  •   News Releases

  • Home:
  • Metabolic Diseases
  • Metabolic Diseases
  • Share
  • Back To Top
  • Facebook
  • Twitter
  • Accessibility
  • Legal Notices
  • Privacy Policy
© 2010-2019 Boehringer Ingelheim (Canada) Ltd./Ltée All rights reserved